BridgeBio Oncology Therapeutics (BBOT) Stock Overview
A clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BBOT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BridgeBio Oncology Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.95 |
| 52 Week High | US$14.87 |
| 52 Week Low | US$4.90 |
| Beta | 0.39 |
| 1 Month Change | -45.36% |
| 3 Month Change | -35.96% |
| 1 Year Change | -52.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBOT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -44.9% | -5.2% | -0.9% |
| 1Y | -52.4% | 37.6% | 14.2% |
Return vs Industry: BBOT underperformed the US Biotechs industry which returned 37.6% over the past year.
Return vs Market: BBOT underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| BBOT volatility | |
|---|---|
| BBOT Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BBOT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BBOT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 88 | Pedro Beltran | bbotx.com |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
BridgeBio Oncology Therapeutics, Inc. Fundamentals Summary
| BBOT fundamental statistics | |
|---|---|
| Market cap | US$396.86m |
| Earnings (TTM) | -US$182.11m |
| Revenue (TTM) | n/a |
Is BBOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBOT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$182.11m |
| Earnings | -US$182.11m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BBOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 06:25 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Oncology Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Robert Burns | H.C. Wainwright & Co. |